Answers are grounded in this paper and cite their sources.
The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or older was similar to that in the other two age groups. (Funded by GlaxoSmithKline Biologicals; ZOE-50 ClinicalTrials.gov number, NCT01165177.).
No takes yet. Share an insight, caveat, or question.
Lal et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: